Search clinical trials for: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)

Total 68 results

Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
Medical College of Wisconsin

Not yet recruiting

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Multiple Myeloma
Chinese PLA General Hospital

Recruiting

CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL

CD19+ Relapse/Refractory B-ALL

China
Memorial Sloan Kettering Cancer Center
Takeda

Active, not recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Burkitt's Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Primary CNS Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma

United States
Shenzhen Fifth People's Hospital

Recruiting

An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects

CAR T-Cell Therapy

China
University of Pennsylvania

Completed

CART-19 for Multiple Myeloma

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Refractory Acute Lymphoblastic Leukemia | Philadelphia-Negative ALL | Philadelphia-Positive ALL | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed ALL, Adult | Refractory Acute Lymphoid Leukemia in Relapse

United States
BioSyngen Pte Ltd

Completed

A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

EBV-positive Nasopharyngeal Carcinoma

China
Beijing Boren Hospital

Recruiting

Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Memorial Sloan Kettering Cancer Center
Juno Therapeutics, Inc.

Active, not recruiting

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Refractory | Relapsed

United States
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Wenbin Qian
Zhejiang Provincial Tongde Hospital

Unknown

Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

B Cell Lymphoma

China
The Children's Hospital of Zhejiang University...
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
He Huang
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Diffuse Large B-cell Lymphoma

China
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

B-cell Acute Lymphoblastic Leukemia

China
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Diffuse Large B-cell Lymphoma

China
Verismo Therapeutics

Recruiting

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Ovarian Cancer | Mesothelioma, Malignant | Cholangiocarcinoma Recurrent

United States
Shanghai Children's Medical Center
Miltenyi Biomedicine GmbH

Unknown

MB-CART19.1 in Patients With R/R ALL

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory
National Institute of Allergy and Infectious Diseases...
University of Pennsylvania Clinical Cell and Vaccine Production Facility...

Recruiting

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Kidney Failure | End Stage Renal Failure on Dialysis | Kidney Transplant

United States
MedImmune LLC
Cambridge Antibody Technology

Terminated

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

Leukemia, Lymphoma, Chronic Lymphocytic | Leukemia, Prolymphocytic Leukemia, Small | Lymphocytic Lymphoma, Moxetumomab Pasudotox

United States, Poland
National Cancer Institute (NCI)

Terminated

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | Lymphoma, Non-hodgkins | B-Cell Chronic Lymphocytic Leukemia

United States
Emory University
National Cancer Institute (NCI); Novartis; Secura Bio, Inc.

Recruiting

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Henan Cancer Hospital
The Beijing Pregene Science and Technology Company, Ltd.

Unknown

The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

B-cell Acute Lymphoblastic Leukemia

China
University of Pennsylvania
University of California, San Francisco

Terminated

Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Henan Cancer Hospital

Recruiting

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Non-hodgkin Lymphoma,B Cell

China
Celyad Oncology SA

Withdrawn

EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 (EPITHINK)

Myelodysplastic Syndromes | AML, Adult
Marcela V. Maus, M.D.,Ph.D.

Recruiting

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
Shire

Completed

Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

Short Bowel Syndrome

United States, Canada, Finland, Belgium, Italy, United Kingdom, Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Takeda

Recruiting

IVIG for Infection Prevention After CAR-T-Cell Therapy

Lymphoma

United States
Sumithira Vasu
National Cancer Institute (NCI)

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
National Cancer Institute (NCI)

Completed

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

Lymphoma, B-Cell | Lymphoma, Non-hodgkins

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Recurrent Glioblastoma | Refractory Glioblastoma

United States
Fred Hutchinson Cancer Center
Mustang Bio

Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI); Mustang Bio, Inc.

Active, not recruiting

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Refractory Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm | Minimal Residual Disease | Acute... and other conditions

United States
Centocor, Inc.

Completed

An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease

Crohn Disease
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ziopharm Oncology

Completed

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Minimal Residual Disease | Small Lymphocytic Lymphoma | Acute Biphenotypic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | CD19 Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
St. Anna Kinderkrebsforschung
Assistance Publique - Hôpitaux de Paris; Australian & New Zealand Children's... and other collaborators

Recruiting

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukaemia

Italy, Israel, Spain, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, Croatia, Czechia, Denmark, Finland, Greece, Malaysia, Mexico, Netherlands, Norway, Poland, Romania, Saudi Arabia, Slovakia, Sweden, Switzerland, Turkey, F... and more
Mehrdad Abedi, MD
National Cancer Institute (NCI)

Recruiting

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (PRIVIG)

Multiple Sclerosis, Relapsing-Remitting

Canada, Israel, United States, Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovakia, Sweden, United Kingdom
Crystal Mackall, MD
California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | CD19 Positive

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Follic Lymph to Diff Large B-Cell Lymphoma | Transformed Marg Zone Lymph to Diff...

United States
Crystal Mackall, MD

Recruiting

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 Positive

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute... and other conditions

United States
Johns Hopkins University
Society of Family Planning

Withdrawn

Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery

Contraception | Bariatric Surgery Candidate

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy; California Institute for Regenerative... and other collaborators

Recruiting

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast Cancer | Neuroendocrine Tumors | Lung Adenocarcinoma | Metastatic Melanoma | Head and Neck Squamous Cell Carcinoma | Refractory Malignant Solid Neoplasm | Thyroid Cancer | Pheochromocytoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Pathologic Stage IIIC Cutaneous Melanoma... and other conditions

United States

Search clinical trials for: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations